期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 566, 期 -, 页码 641-651出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2019.05.068
关键词
Nanocrystals; Spray drying; Ciprofloxacin; Liposomes; Controlled drug release
资金
- Australian Research Council [LP160101498]
- Aradigm Corporation
- Australian Research Council [LP160101498] Funding Source: Australian Research Council
This study was conducted to evaluate the feasibility of developing inhalable dry powders of liposomal encapsulated ciprofloxacin nanocrystals (LECN) for controlled drug release. Dry powders of LECN were produced by freeze-thaw followed by spray drying. The formulations contained sucrose as a lyoprotectant in different weight ratios (0.75:1, 1:1 and 2:1 sucrose to lipids), along with 2% magnesium stearate and 5% isoleucine as aerosolization enhancers. The powder physical properties (particle size, morphology, crystallinity, moisture content), in vitro aerosolization performance, drug encapsulation efficiency and in vitro drug release were investigated. The spray dried powders were comprised of spherical particles with a median diameter of similar to 1 mu m, partially crystalline, with a low water content ( similar to 2% mass) and did not undergo recrystallization at high relative humidity. When dispersed by an Osmohaler (R) inhaler at 100 L/min, the powders showed a high aerosol performance with a fine particle fraction (% wt. < 5 mu m) of 66-70%. After reconstitution of the powders in saline, ciprofloxacin nanocrystals were confirmed by cryo-electron microscopy. The drug encapsulation efficiency of the reconstituted liposomes was 71-79% compared with the stock liquid formulation. Of the three formulations, the one containing a sucrose to lipids wt. ratio of 2:1 demonstrated a prolonged release of ciprofloxacin from the liposomes. In conclusion, ciprofloxacin nanocrystal liposomal powders were prepared that were suitable for inhalation aerosol delivery and controlled drug release.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据